Polyarylate compounds and their applications

By developing a new polyaryl compound, the drug resistance of EGFR kinase inhibitors to C797S mutant tumors was achieved, and the existing tumor inhibition effect was solved. The problem of poor treatment of C797S mutant tumors in the technology.

CN115715289BActive Publication Date: 2024-12-03JIANGSU SIMCERE PHARMA CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202180039658.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-06-03
Filing Date
2021-06-01
Publication Date
2024-12-03
Estimated Expiration
2041-06-01

AI Technical Summary

Technical Problem

The existing EGFR tyrosine kinase inhibitors are difficult to effectively inhibit the drug resistance of C797S mutations in EGFR gene mutations, resulting in a reduction in therapeutic effect. In particular, the third-generation irreversible inhibitors have limited inhibitory activity on C797S mutations.

Method used

Develop a novel polyaryl compound or a pharmaceutically acceptable salt thereof by binding specific compound structures as an EGFR kinase inhibitor to prevent or treat EGFR-mediated diseases, especially against C797S mutant tumor cells. The compound structure includes specific groups such as R1, R2, X, Q1, Q2, L, etc., and is prepared through a specific chemical synthesis route to form a compound that has efficient inhibition of EGFR tyrosine kinase activity.

Benefits of technology

This compound showed significant tumor inhibition effect on the EGFR-Del19/T790M/C797S subcutaneous tumor model, with a good dose-response relationship, which can effectively inhibit tumor growth, and provides a new solution to treat C797S mutation resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115715289B_ABST
    Figure CN115715289B_ABST
Patent Text Reader

Abstract

The present invention provides a novel polyaryl compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing them, and use thereof as an EGFR kinase inhibitor in preventing or treating related diseases. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to a prior application filed with the State Intellectual Property Office of China on June 3, 2020, with patent application number CN202010495249.X and invention title “Polyarylate Compounds and Applications”. The entire text of the prior application is incorporated into this application by reference. Technical Field

[0002] The present invention relates to a novel polyaryl compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the same and use thereof as an EGFR kinase inhibitor in preventing or treating related diseases. Background Art

[0003] EGFR (Epidermal Growth Factor Receptor) is a receptor for epithelial growth factor (EGF) cell proliferation and signal transduction. EGFR belongs to the ErbB receptor family, which includes EGFR (ErbB-1), HER2 / c-neu (ErbB-2), HER3 (ErbB-3) and HER4 (ErbB-4). EGFR is also known as HER1 and ErbB1. EGFR is widely distributed on the cell surface of mammalian epithelial cells, fibroblasts, glial cells, keratinocytes, etc. The EGFR signaling pathway plays an important role in physiological processes such as cell growth, proliferation and differentiation. EGFR is divided into three regions: the extracellular ligand binding region, the transmembrane region and the intracellular kinase region. When EGFR is bound by the corresponding ligand, it will induce it to form homo- or hetero-dimers, thereby activating the intracellular tyrosine kinase pathway and causing it to phosphorylate itself, thereby guiding downstream phosphorylation, including MAPK, Akt and JNK pathways, and inducing cell proliferation.

[0004] EGFR tyrosine kinase inhibitors (TKIs) inhibit receptor phosphorylation and activation of downstream signal transduction molecules by blocking endogenous ATP from binding to the intracellular kinase region, thereby blocking the proliferation of tumor cells. Although EGFR targeted therapy has successfully entered the clinical stage and drugs are available on the market, EGFR gene mutations lead to drug resistance. Its mutations mainly occur in exons 18-21, among which exon 19 deletion and exon 21 L858R point mutation are the most common mutation subtypes, accounting for 90% of all mutation types. With the development and use of drugs, most resistance occurs in the secondary mutation of T790M in the gatekeeper region of kinase. The third-generation irreversible inhibitors developed in recent years have good inhibitory activity against T790M mutations, but C797S mutations are also inevitable, and are the main resistance mechanism of the star drug AZD9291 (about 40%). In 2018, AZD9291 has entered the first-line treatment. Targeting the C797S mutation, people are in urgent need of developing new, safer and more effective EGFR TKIs. Summary of the invention

[0005] The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof:

[0006]

[0007] in,

[0008] R 1 is selected from phenyl and 5-6 membered heteroaryl, wherein the phenyl and 5-6 membered heteroaryl are optionally replaced by R 1a replace;

[0009] R 2 is selected from H, halogen, cyano or C1-C6 alkyl, wherein the C1-C6 alkyl is optionally replaced by R 2a replace;

[0010] X is selected from CH or N;

[0011] Q1 is selected from a chemical bond or a 4-12 membered heterocyclic group, wherein the 4-12 membered heterocyclic group is optionally replaced by R 3a replace;

[0012] Q2 is selected from 4-12 membered heterocyclic groups, wherein the 4-12 membered heterocyclic groups are optionally substituted by R 4a replace;

[0013] L is selected from C1-C3 alkylene, C1-C3 alkylene-O, C(═O), NH, N(C1-C3 alkyl), O or S;

[0014] R 1a , R2a independently selected from halogen, CN, OH, C1-C6 alkoxy or optionally R b Substituted with the following groups: NH2, C1-C6 alkyl;

[0015] R 3a , R 4a independently selected from halogen, CN, oxo, OH, C1-C6 alkoxy, C1-C3 acyl or optionally R b Substituted with the following groups: NH2, C1-C6 alkyl, C3-C6 cycloalkyl or 3-6 membered heterocyclic group;

[0016] R b Independently selected from halogen, CN, OH, NH2, C1-C3 alkyl or C1-C3 alkoxy.

[0017] In some embodiments, R 1 is selected from 5-6 membered heteroaryl, wherein the 5-6 membered heteroaryl is optionally substituted by R 1a replace.

[0018] In some embodiments, R 1 is selected from 5-membered heteroaryl, the 5-membered heteroaryl is optionally substituted by R 1a replace.

[0019] In some embodiments, R 1 is selected from the group consisting of pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl and triazolyl, wherein the pyrrolyl, furanyl, thienyl, imidazolyl, pyrazolyl and triazolyl are optionally substituted by R 1a replace.

[0020] In some embodiments, R 1 is selected from pyrazolyl, the pyrazolyl being optionally substituted by R 1a replace.

[0021] In some embodiments, R 1a is selected from halogen, CN or C1-C3 alkyl optionally substituted by OH.

[0022] In some embodiments, R 1a Selected from methyl or CH2CH2OH.

[0023] In some embodiments, R 1 Selected from

[0024] In some embodiments, R 2 Selected from H, halogen, cyano or C1-C3 alkyl.

[0025] In some embodiments, R 2 is selected from H, halogen or cyano.

[0026] In some embodiments, R 2 Selected from halogen.

[0027] In some embodiments, R 2 Selected from Br or Cl.

[0028] In some embodiments, R 2 Selected from Br.

[0029] In some embodiments, X is selected from CH.

[0030] In some embodiments, Q1 is selected from a chemical bond or a 4-7 membered heterocyclylene group, wherein the 4-7 membered heterocyclylene group is optionally replaced by R 3a replace.

[0031] In some embodiments, Q1 is selected from a chemical bond or a 5-6 membered heterocyclylene group, wherein the 5-6 membered heterocyclylene group is optionally replaced by R 3a replace.

[0032] In some embodiments, Q1 is selected from a chemical bond or a 6-membered heterocyclyl group, wherein the 6-membered heterocyclyl group is optionally replaced by R 3a replace.

[0033] In some embodiments, Q1 is selected from a chemical bond or a 6-membered heterocyclic group containing 1-2 heteroatoms selected from N or O, and the 6-membered heterocyclic group is optionally replaced by R 3a replace.

[0034] In some embodiments, Q1 is selected from a chemical bond or a 6-membered heterocycloalkylene group containing 1-2 heteroatoms selected from N or O, and the 6-membered heterocycloalkylene group is optionally replaced by R 3a replace.

[0035] In some embodiments, Q1 is selected from a chemical bond, Said Optional R 3a replace.

[0036] In some embodiments, R 3a Selected from halogen, cyano or C1-C3 alkyl.

[0037] In some embodiments, R 3a Selected from halogen or methyl.

[0038] In some embodiments, R 3a Selected from F or methyl.

[0039] In some embodiments, Q2 is selected from 4-8 membered heterocyclyl, wherein the 4-8 membered heterocyclyl is optionally replaced by R 4a replace.

[0040] In some embodiments, Q2 is selected from 4-8 membered heterocyclic groups, wherein the 4-8 membered heterocyclic groups contain 1-2 heteroatoms selected from N or O, wherein the 4-8 membered heterocyclic groups are optionally replaced by R 4a replace.

[0041] In some embodiments, Q2 is selected from 4-8 membered heterocycloalkyl, the 4-8 membered heterocycloalkyl containing 1-2 heteroatoms selected from N or O, the 4-8 membered heterocycloalkyl optionally replaced by R 4a replace.

[0042] In some embodiments, Q2 is selected from Said Optional R 4a replace.

[0043] In some embodiments, R 4a is selected from halogen, oxo, C1-C3 acyl, C1-C3 alkyl or NH2 optionally substituted by C1-C3 alkyl.

[0044] In some embodiments, R 4a Selected from F, oxo, acetyl, methyl or N(CH3)2.

[0045] In some embodiments, L is selected from CH2, CH2O, CH2CH2CH2O, C(=O), NCH3 or O.

[0046] In some embodiments, the structural unit Selected from

[0047]

[0048] In some embodiments, the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is selected from the following compounds or a pharmaceutically acceptable salt thereof:

[0049]

[0050]

[0051] On the other hand, the present application relates to a pharmaceutical composition, which comprises a compound of formula (I) of the present application or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

[0052] On the other hand, the present application relates to a method for treating a disease mediated by EGFR in a mammal, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to a mammal, preferably a human, in need of such treatment.

[0053] On the other hand, the present application relates to the use of the compound of formula (I) or its pharmaceutically acceptable salt, or its pharmaceutical composition in the preparation of drugs for preventing or treating EGFR-mediated diseases.

[0054] On the other hand, the present application relates to the use of the compound of formula (I) or its pharmaceutically acceptable salt, or its pharmaceutical composition in preventing or treating EGFR-mediated diseases.

[0055] On the other hand, the present application relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof for preventing or treating EGFR-mediated diseases.

[0056] In some embodiments, the EGFR-mediated disease is a tumor.

[0057] Definitions and explanations of terms

[0058] Unless otherwise specified, the definitions of groups and terms recorded in the specification and claims of the present invention, including their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, definitions of specific compounds in examples, etc., can be arbitrarily combined and coupled with each other. The group definitions and compound structures after such combinations and couplings shall fall within the scope of the description of the present invention.

[0059] The term "pharmaceutically acceptable salt" refers to salts of pharmaceutically acceptable non-toxic acids or bases, including salts of inorganic acids and bases, and organic acids and bases.

[0060] The term "stereoisomer" refers to isomers resulting from different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, diastereomers and conformational isomers.

[0061] The compounds of the present invention may have asymmetric atoms such as carbon atoms, sulfur atoms, nitrogen atoms, phosphorus atoms (optical centers) or asymmetric double bonds. Racemates, enantiomers, diastereomers, geometric isomers and individual isomers are all included within the scope of the present invention.

[0062] The graphic representation of racemates or enantiomerically pure compounds herein is from Maehr, J. Chem. Ed. 1985, 62: 114-120. Unless otherwise indicated, wedge-shaped bonds and dashed bonds are used to represent the absolute configuration of a stereocenter. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, they include E and Z geometric isomers unless otherwise specified. Likewise, all tautomeric forms are included within the scope of the present invention.

[0063] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as mixtures enriched in enantiomers or diastereomers, all of which are within the scope of the present invention. Additional asymmetric carbon atoms, asymmetric sulfur atoms, asymmetric nitrogen atoms or asymmetric phosphorus atoms may be present in substituents such as alkyl. All of these isomers and their mixtures are included within the scope of the present invention. The compounds containing asymmetric atoms of the present application can be isolated in optically pure form or in racemic form. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral raw materials or chiral reagents.

[0064] The term "tautomer" refers to functional group isomers resulting from the rapid movement of an atom in a molecule between two positions. The compounds of the present invention may exhibit tautomerism. Tautomeric compounds may exist in two or more interconvertible species. Prototropic tautomers arise from the migration of a covalently bonded hydrogen atom between two atoms. Tautomers generally exist in equilibrium, and attempts to separate a single tautomer usually produce a mixture whose physicochemical properties are consistent with a mixture of compounds. The position of equilibrium depends on the chemical characteristics within the molecule. For example, in many aliphatic aldehydes and ketones such as acetaldehyde, the keto form predominates; while in phenols, the enol form predominates. The present invention encompasses all tautomeric forms of the compounds.

[0065] The term "pharmaceutical composition" refers to a mixture of one or more compounds described herein or their physiologically / pharmaceutically acceptable salts with other chemical components, such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of the compound to an organism.

[0066] The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, as long as the valence state of the particular atom is normal and the substituted compound is stable. When the substituent is oxo (i.e., =O), it means that two hydrogen atoms are replaced, and oxo will not occur on an aromatic group.

[0067] The term "optional" or "optionally" means that the event or situation described subsequently may or may not occur, and the description includes the occurrence of the event or situation and the non-occurrence of the event or situation. For example, an ethyl group is "optionally" substituted with a halogen, meaning that the ethyl group may be unsubstituted (CH2CH3), monosubstituted (such as CH2CH2F, etc.), polysubstituted (such as CHFCH2F, CH2CHF2, etc.) or fully substituted (such as CF2CF3, etc.). It will be appreciated by those skilled in the art that for any group comprising one or more substituents, no substitution or substitution pattern that is sterically impossible to exist and / or cannot be synthesized will be introduced.

[0068] When a substituent is selected from a chemical bond, it means that the two groups connected are directly connected, for example, when the structural unit When Q1 in is selected from a chemical bond, the structure represented by the above structural unit is

[0069] If the connecting group mentioned in this article does not specify its connecting direction, then its connecting direction is arbitrary. When L is selected from "C1-C3 alkylene-O", L can connect ring Q2 and Q1 from left to right to form "Q2-C1-C3 alkylene-O-Q1", or connect ring Q2 and Q1 from left to right to form "Q2-O-C1-C3 alkylene-Q1".

[0070] The term "halo" or "halogen" refers to fluorine, chlorine, bromine and iodine.

[0071] The term "C1-C6 alkyl" is understood to mean a straight-chain or branched saturated monovalent hydrocarbon radical having 1, 2, 3, 4, 5 or 6 carbon atoms. The alkyl group is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl or 1,2-dimethylbutyl, etc.; preferably, "C1-C6 alkyl" may include "C1-C3 alkyl", and "C1-C3 alkyl" should be understood to mean a straight or branched saturated monovalent hydrocarbon group having 1, 2 or 3 carbon atoms.

[0072] The term "alkylene" refers to a divalent group formed by removing a hydrogen atom from an "alkyl" group.

[0073] The term "C1-C6 alkoxy" may be understood as "C1-C6 alkyloxy" or "C1-C6 alkyl-O-".

[0074] The term "C1-C3 acyl" refers to formyl, acetyl or propionyl.

[0075] The term "C3-C6 cycloalkyl" is understood to mean a saturated monovalent monocyclic or bicyclic hydrocarbon ring having 3 to 6 carbon atoms.

[0076] The term "heterocyclyl" refers to a monocyclic heterocyclic group or a fused heterocyclic group system; the fused heterocyclic ring includes a bis-heterocyclic group, a spiro-heterocyclic group, and a bridged heterocyclic group, which may be saturated or partially saturated, but not aromatic.

[0077] The term "4-12 membered heterocyclyl" means a saturated or partially saturated monovalent monocyclic, cyclic, spirocyclic or bridged ring containing 1-5, preferably 1-3 heteroatoms selected from N, O, B and S. In particular, the heterocyclyl may include, but is not limited to, a 4-membered ring such as azetidinyl, oxetanyl; a 5-membered ring such as tetrahydrofuranyl, dioxolyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl, 1,3,2-dioxaborolanyl; or a 6-membered ring such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl or trithianyl; or a partially saturated 6-membered ring such as tetrahydropyridinyl; or a 7-membered ring such as diazepanyl. Optionally, the heterocyclyl may be benzo-fused. The heterocyclic group may be bicyclic, for example, but not limited to, a 5,5-membered ring, such as a hexahydrocyclopenta[c]pyrrol-2(1H)-yl ring, or a 5,6-membered bicyclic ring, such as a hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl ring. The ring containing the nitrogen atom may be partially unsaturated, i.e., it may contain one or more double bonds, for example, but not limited to, 2,5-dihydro-1H-pyrrolyl, 4H-[1,3,4]thiadiazinyl, 4,5-dihydrooxazolyl or 4H-[1,4]thiazinyl, or it may be benzo-fused, for example, but not limited to, dihydroisoquinolinyl. Optionally, the "4-12 membered heterocyclyl" may be a "4-12 membered heterocycloalkyl", "4-12 membered heterocycloalkyl" means a saturated, monovalent monocyclic, cyclic, spirocyclic or bridged ring containing 1-5 heteroatoms selected from N, O, B and S; preferably, the "4-12 membered heterocyclyl" includes "4-8 membered heterocyclyl", "4-7 membered heterocyclyl", "5-6 membered heterocyclyl", and also includes "4-8 membered heterocycloalkyl", "4-7 membered heterocycloalkyl", "5-6 membered heterocycloalkyl" and the like; the term "3-6 membered heterocyclyl" refers to a heterocyclyl having 3 to 6 ring atoms and containing 1-3 heteroatoms selected from N, O, B and S. According to the present invention, the heterocyclyl is non-aromatic.

[0078] The term "heterocyclylene" means a divalent group formed by removing a hydrogen atom from a "heterocyclyl" group.

[0079] The term "heteroaryl" is understood to include monovalent monocyclic, bicyclic or tricyclic aromatic ring systems having 5 to 20 ring atoms and containing 1-5 heteroatoms independently selected from N, O and S; "5-6 membered heteroaryl" refers to a group having 5 or 6 ring atoms and containing 1-4, preferably 1-3, heteroatoms independently selected from N, O and S. Preferably, the "5-6 membered heteroaryl" can be selected from thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl, etc.

[0080] The term "treatment" means administering the compound or formulation described herein to prevent, improve or eliminate a disease or one or more symptoms associated with the disease, and includes:

[0081] (i) preventing a disease or disease state from occurring in a mammal, particularly where such mammal is susceptible to such disease state but has not yet been diagnosed as having such disease state;

[0082] (ii) inhibiting a disease or disease state, i.e., arresting its development;

[0083] (iii) ameliorating a disease or condition, even if causing regression of the disease or condition.

[0084] The term "therapeutically effective amount" means an amount of a compound of the present invention that (i) treats or prevents a specific disease, condition, or disorder, (ii) alleviates, ameliorates, or eliminates one or more symptoms of a specific disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a specific disease, condition, or disorder described herein. The amount of a compound of the present invention that constitutes a "therapeutically effective amount" varies depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by those skilled in the art based on their own knowledge and this disclosure.

[0085] The term "excipient" refers to a pharmaceutically acceptable inert ingredient. Examples of the term "excipient" include, but are not limited to, binders, disintegrants, lubricants, glidants, stabilizers, fillers, and diluents. Excipients can enhance the handling characteristics of a pharmaceutical preparation, i.e., make the preparation more suitable for direct compression by increasing fluidity and / or adhesion. Examples of typical "pharmaceutically acceptable carriers" suitable for the above-mentioned preparations are: sugars, starches, cellulose and its derivatives, etc., which are commonly used excipients in pharmaceutical preparations.

[0086] The term "pharmaceutically acceptable excipients" refers to those excipients that have no significant irritation to the organism and do not impair the biological activity and performance of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.

[0087] The words “comprise”, “comprise” or “comprises” and their English variations such as comprises or comprising should be construed in an open, non-exclusive sense, ie, “including but not limited to”.

[0088] The compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include but are not limited to the embodiments of the present invention.

[0089] The present application also includes isotopically labeled compounds of the present application that are identical to those described herein, but in which one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present application include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 123 I. 125 I and 36 Cl et al.

[0090] Certain isotope-labeled compounds of the present application (e.g. 3 H and 14 C-labeled) can be used in compound and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e. 14 C) isotopes are particularly preferred due to their ease of preparation and detectability. Positron emitting isotopes such as 15 O. 13 N. 11 C and18 F can be used in positron emission tomography (PET) studies to determine substrate occupancy. Isotopically labeled compounds of the present application can generally be prepared by following procedures analogous to those disclosed in the Schemes and / or Examples below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

[0091] In addition, the use of heavier isotopes such as deuterium (i.e. 2 H)) substitution may offer certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and may therefore be preferred in certain circumstances, wherein deuterium substitution may be partial or complete, partial deuterium substitution meaning that at least one hydrogen is replaced by at least one deuterium.

[0092] The pharmaceutical composition of the present application can be prepared by combining the compound of the present application with suitable pharmaceutically acceptable excipients, for example, it can be formulated into solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols, etc.

[0093] Typical routes of administration of the compounds of the present application or their pharmaceutically acceptable salts or their pharmaceutical compositions include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, vaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.

[0094] The pharmaceutical composition of the present application can be manufactured by methods well known in the art, such as conventional mixing methods, dissolution methods, granulation methods, sugar-coated pill making methods, grinding methods, emulsification methods, freeze-drying methods, etc.

[0095] In some embodiments, the pharmaceutical composition is in oral form. For oral administration, the pharmaceutical composition can be prepared by mixing the active compound with pharmaceutically acceptable excipients well known in the art. These excipients enable the compounds of the present application to be formulated into tablets, pills, lozenges, dragees, capsules, liquids, gels, slurries, suspensions, etc., for oral administration to patients.

[0096] Solid oral compositions can be prepared by conventional mixing, filling or tableting methods. For example, they can be obtained by mixing the active compound with a solid excipient, optionally grinding the resulting mixture, adding other suitable excipients if necessary, and then processing the mixture into particles to obtain a tablet or dragee core. Suitable excipients include, but are not limited to, adhesives, diluents, disintegrants, lubricants, glidants or flavoring agents, etc.

[0097] The pharmaceutical composition may also be suitable for parenteral administration, such as sterile solutions, suspensions or lyophilized products in appropriate unit dosage forms.

[0098] In all administration methods described herein, the daily dosage of the compound of formula I is 0.01 to 100 mg / kg body weight, preferably 0.05 to 50 mg / kg body weight, more preferably 0.1 to 30 mg / kg body weight, in the form of single or divided doses.

[0099] The chemical reactions of the specific embodiments of the present invention are carried out in a suitable solvent, which must be suitable for the chemical changes of the present invention and the reagents and materials required. In order to obtain the compounds of the present invention, it is sometimes necessary for those skilled in the art to modify or select the synthesis steps or reaction processes based on the existing embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0100] Figure 1 This is the tumor growth curve of the PC9-EGFR-Del19 / T790M / C797S subcutaneous tumor model of Test Example 3. DETAILED DESCRIPTION

[0101] The following examples illustrate the technical solutions of the invention in detail, but the protection scope of the present invention includes but is not limited to them.

[0102] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). The units of NMR shifts are 10 -6 (ppm). The solvents for NMR determination are deuterated dimethyl sulfoxide, deuterated chloroform, deuterated methanol, etc., and the internal standard is tetramethylsilane (TMS); "IC 50 ” refers to the half inhibitory concentration, which refers to the concentration at which half of the maximum inhibitory effect is achieved.

[0103] Example 1. Preparation of (6-((5-bromo-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-((1-methylpiperidin-4-yl)methoxy)phenyl)amino)pyrimidin-4-yl)amino)quinoxaline-5-yl)-dimethylphosphine oxide trifluoroacetate (Compound 1)

[0104]

[0105] Compound 1-2:

[0106]

[0107] Quinoxaline-6-amine (5.0 g, 34.48 mmol) was dissolved in acetic acid (150 mL) at room temperature, and a solution of iodine chloride (6.1 g, 37.58 mmol) in acetic acid (55 mL) was slowly added dropwise to the reaction solution, and the reaction solution was stirred at 20°C under an argon atmosphere for 2 hours until the reaction was complete. The reaction solution was directly concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent gradient: ethyl acetate: petroleum ether = 1:20 to 1:3) to obtain 5-iodoquinoxaline-6-amine (1-2) (6.0 g, yield: 67%).

[0108] LCMS:Rt:1.325min;MS m / z(ESI):272.1[M+H] + .

[0109] Compound 1-3:

[0110]

[0111] 5-Iodoquinoxaline-6-amine (1-2) (6.0 g, 22.1 mmol), dimethylphosphine oxide (2.6 g, 33.2 mmol) and potassium phosphate (7.0 g, 33.2 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.2 g, 2.2 mmol), palladium acetate (494 mg, 2.2 mmol) were dissolved in N,N-dimethylformamide (100 mL) and water (20 mL) at room temperature. The reaction solution was heated to 120 ° C under an argon atmosphere and stirred for 24 hours until the reaction was complete. The reaction solution was directly concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent gradient: ethyl acetate: petroleum ether = 1:10 to 1:1) to obtain (6-aminoquinoxaline-5-yl) dimethylphosphine oxide (1-3) (4.0 g, yield: 67%).

[0112] LCMS:Rt:0.902min;MS m / z(ESI):222.1[M+H] + .

[0113] Compound 1-4:

[0114]

[0115] At room temperature, (6-aminoquinoxaline-5-yl)dimethylphosphine oxide (1-3) (1.0 g, 4.52 mmol) was dissolved in ethanol (20 mL), and 5-bromo-2,4-dichloropyrimidine (2.0 g, 9.04 mmol) and N,N-diisopropylethylamine (3.5 g, 27.1 mmol) were added. The reaction solution was heated to 120 ° C under argon protection and stirred for 72 hours until the reaction was complete. The reaction solution was directly concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent gradient: ethyl acetate: petroleum ether = 1:10 to 1:1) to obtain (6-((5-bromo-2-chloropyrimidin-4-yl)amino)quinoxaline-5-yl)dimethylphosphine oxide (1-4) (0.5 g, yield: 27%).

[0116] LCMS:Rt:1.453min;MS m / z(ESI):411.9[M+H] + .

[0117] Compounds 1-5:

[0118]

[0119] 2-Methoxy-4-fluoro-5-bromo-nitrobenzene (3.00 g, 12.00 mmol) was dissolved in tetrahydrofuran (55 mL) at room temperature. Under argon protection, the reaction was placed in an ice-water bath at 0 ° C, and sodium hydride (1.44 g, 36.00 mmol) was added in batches. After the addition was completed, the reaction was stirred at room temperature for 30 minutes, and 1-tert-butyloxycarbonyl-4-hydroxymethylpiperidine (3.87 g, 18.00 mmol) was dissolved in tetrahydrofuran (5 mL) and added dropwise to the reaction. After the addition was completed, the reaction was continued to stir at room temperature for 3 hours. The reaction was detected by LCMS, and most of the raw materials had reacted and the product was detected. Saturated ammonium chloride solution was slowly added to the reaction solution to quench the reaction, poured into water (500 mL), extracted with ethyl acetate (200 mL X 2), the organic phases were combined and washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained crude product was separated and purified by silica gel column chromatography (dichloromethane:methanol=30:1) to obtain tert-butyl 4-((2-bromo-5-methoxy-4-nitrophenoxy)methyl)piperidine-1-carboxylate (1-5) (2.31 g, yield: 43.3%).

[0120] LCMS:Rt:2.070min;MS m / z(ESI):345.1[M-100+H] + .

[0121] Compounds 1-6:

[0122]

[0123] At room temperature, tert-butyl 4-((2-bromo-5-methoxy-4-nitrophenoxy)methyl)piperidine-1-carboxylate (1-5) (2.31 g, 5.19 mmol) was dissolved in methanol (20 mL) and stirred at room temperature, and then hydrogen chloride / 1,4-dioxane (4.0 M, 8.0 mL, 32.00 mol) was added. After the addition was completed, the reaction was stirred at room temperature for 2 hours. According to LCMS detection, the raw material had reacted completely and the product was detected. The reaction was stopped and the vacuum was dried to obtain 4-((2-bromo-5-methoxy-4-nitrophenoxy)methyl)piperidine hydrochloride (1-6) (2.01 g, crude product, yield: 100.0%), which was directly used in the next step.

[0124] LCMS:Rt:0.969min;MS m / z(ESI):345.0[M+H] + .

[0125] Compound 1-7:

[0126]

[0127] 4-((2-bromo-5-methoxy-4-nitrophenoxy)methyl)piperidine hydrochloride (1-6) (1.21 g, 3.51 mmol) was dissolved in methanol (15 mL) at room temperature and stirred at room temperature. Formaldehyde aqueous solution (18.5 mL, 226 mmol, wt 37%) and acetic acid (0.53 mL, 8.79 mmol) were added and stirred at room temperature for 30 minutes. Sodium triacetyl borohydride (1.12 g, 5.27 mmol) was added in batches. After the addition was completed, the reaction was continued at room temperature for 14 hours. The reaction was detected by LCMS, and the raw materials had reacted completely and the product was detected. Stop the reaction. Pour the reaction solution into saturated sodium bicarbonate solution (300 mL), extract with ethyl acetate (100 mL x 2), combine the organic phases and wash with saturated brine (80 mL), dry over anhydrous sodium sulfate, and filter. The filtrate was concentrated under reduced pressure and dried. The obtained crude product was separated and purified by silica gel column chromatography (dichloromethane:methanol=20:1) to obtain 4-((2-bromo-5-methoxy-4-nitrophenoxy)methyl)-1-methylpiperidine (1-7) (1.03 g, yield: 81.3%).

[0128] LCMS:Rt:0.980min;MS m / z(ESI):359.0[M+H] + .

[0129] Compound 1-8:

[0130]

[0131] 4-((2-bromo-5-methoxy-4-nitrophenoxy)methyl)-1-methylpiperidine (1-7) (500 mg, 1.39 mmol) and 1-methylpyrazole-4-boronic acid pinacol ester (319 mg, 1.531 mmol) were dissolved in 1,4-dioxane (10 mL) and stirred at room temperature. Sodium carbonate (443 mg, 4.18 mmol) was dissolved in water (1.0 mL) and added to the reaction. Under argon protection, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (57 mg, 0.07 mmol) was added, and the reaction was placed in an oil bath at 100°C and heated and stirred for 14 hours. The reaction was detected by LCMS, and the raw materials had reacted completely and the product was detected. The reaction was stopped and cooled to room temperature, and the reaction solution was concentrated to dryness under reduced pressure. The obtained crude product was separated and purified by silica gel column chromatography (dichloromethane:methanol=20:1) to obtain 4-((5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)-4-nitrophenoxy)methyl)-1-methylpiperidine (1-8) (200 mg, yield: 40.0%).

[0132] LCMS:Rt:0.930min;MS m / z(ESI):361.2[M+H] + .

[0133] Compound 1-9:

[0134]

[0135] 4-((5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)-4-nitrophenoxy)methyl)-1-methylpiperidine (1-8) (200 mg, 0.56 mmol) was dissolved in methanol (10 mL) at room temperature and stirred at room temperature, and wet palladium / carbon (59 mg (Pd>=10%, H2O wt%=50%)) was added. After the addition was completed, the reaction was placed under a hydrogen atmosphere (15 psi) and stirred at room temperature for 3 hours. According to LCMS detection, the raw material had reacted completely and the product was detected. The reaction was stopped, the reaction solution was filtered through a diatomaceous earth layer, the filter cake was washed with dichloromethane (30 mL), and the filtrate was concentrated under reduced pressure and dried to obtain 2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-((1-methylpiperidin-4-yl)methoxy)aniline (1-9) (171 mg, yield: 93.2%).

[0136] LCMS:Rt:0.980min;MS m / z(ESI):331.1[M+H] + .

[0137] Compound 1:

[0138]

[0139] (6-((5-bromo-2-chloropyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide (1-4) (213 mg, 0.52 mmol) and 2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-((1-methylpiperidin-4-yl)methoxy)aniline (1-9) (171 mg, 0.52 mmol) were dissolved in isopropanol (8 mL) at room temperature and stirred at room temperature, and trifluoroacetic acid (0.4 mL, 5.17 mmol) was added. After the addition was completed, the reaction was placed in an oil bath at 100°C and heated under reflux for 14 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The crude product was purified by preparative high performance liquid chromatography (eluent gradient see the table below) to give (6-((5-bromo-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-((1-methylpiperidin-4-yl)methoxy)phenyl)amino)pyrimidin-4-yl)amino)quinoxaline-5-yl)-dimethylphosphine oxide trifluoroacetate (Compound 1) (84 mg, yield: 23.0%).

[0140]

[0141] 1 H NMR(400MHz,MeOD)δ:8.86(s,1H),8.84(s,1H),8.75(br,1H),8.27(s,1H),7.76(s,1H),7.73(s,1H),7.53(br,2H),6.86(s,1H),4. 22-4.17(m,2H),3.90(s,3H),3.77(s,3H),3.63-3.59(m,2H),3.13-3.07(m,2H),2.90(s,3H),2.22-2.13(m,9H),1.68-1.65(m,2H).

[0142] 19 F NMR (376.5MHz, MeOD) δ: -78.052

[0143] 31 P NMR (162.0MHz, MeOD) δ: 52.41.

[0144] LCMS: Rt:3.917min; MS m / z(ESI):706.1,708.1[M+H] + .

[0145] Example 2, Preparation of (6-((5-bromo-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(4-(morpholinomethyl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide trifluoroacetate (Compound 2)

[0146]

[0147] Compound 2-2:

[0148]

[0149] The compound 4-formylpiperidine-1-carboxylic acid benzyl ester (1.0 g, 4.05 mmol) and morpholine (0.39 g, 4.45 mmol) were dissolved in 1,2-dichloroethane (10 mL) at room temperature, and then acetic acid (0.36 g, 6.07 mmol) was added. The reaction solution was stirred at room temperature for 2 hours under argon protection, and sodium acetate borohydride (1.72 g, 8.10 mmol) was added and reacted at room temperature for 16 hours. LCMS detected that the reaction was complete. The reaction solution was added to a saturated sodium bicarbonate aqueous solution (20 mL), extracted with dichloromethane (30 mL x 2), and the organic phases were combined and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to obtain 4-(morpholinemethyl)piperidine-1-carboxylic acid benzyl ester (2-2) (1.5 g crude product, yield: 100%).

[0150] LCMS:Rt:0.806min;MS m / z(ESI):319.6[M+H] + .

[0151] Compound 2-3:

[0152]

[0153] The compound 4-(morpholinemethyl)piperidine-1-carboxylic acid benzyl ester (2-2) (1.5 g, 4.71 mmol) was dissolved in ethanol (15 mL) at room temperature and wet palladium / carbon (150 mg, 10% (Pd>=10%, H2O wt%=50%)) was added. The reaction solution was stirred at room temperature under a hydrogen atmosphere overnight. TLC (petroleum ether / ethyl acetate=3 / 1) showed that the reaction was complete. The reaction solution was filtered through diatomaceous earth to remove the catalyst, and the filtrate was concentrated under reduced pressure to obtain the crude intermediate 4-(piperidin-4-ylmethyl)morpholine (2-3) (0.86 g, yield: 100%), which was directly used in the next step.

[0154] LCMS:Rt:0.331min; MS m / z(ESI):185.2[M+H] + .

[0155] Compound 2-4:

[0156]

[0157] Compound 4-(piperidin-4-ylmethyl)morpholine (2-3) (334 mg, 1.82 mmol) and 1-bromo-2-fluoro-4-methoxy-5-nitrobenzene (500 mg, 2.0 mmol) were dissolved in acetonitrile (5 mL) at room temperature. The reaction solution was heated to 60°C under argon protection and stirred for 16 hours until the reaction was complete. The reaction solution was filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent gradient: methanol: dichloromethane = 1:30 to 1:10) to obtain 4-((1-(2-bromo-5-methoxy-4-nitrophenyl)piperidin-4-yl)methyl)morpholine (2-4) (400 mg, yield: 53.1%).

[0158] LCMS:Rt:0.922min; MS m / z(ESI):414.1[M+H] + .

[0159] Compound 2-5:

[0160]

[0161] 4-((1-(2-bromo-5-methoxy-4-nitrophenyl)piperidin-4-yl)methyl)morpholine (2-4) (400 mg, 0.964 mmol), 1-methylpyrazole-4-boronic acid pinacol ester (200 mg, 0.964) and sodium carbonate (204 mg, 1.93 mmol) were added to a mixed solvent of 1,4-dioxane and water (1,4-dioxane: water = 5:1, 12 mL) at room temperature, the system was evacuated and filled with argon three times, and then [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (70 mg, 0.0964 mmol) was added, and the system was evacuated and filled with argon three times. The reaction solution was heated to 100°C and stirred for 2 hours. After the reaction was complete by LCMS, the reaction solution was cooled to room temperature. The reaction solution was added to water (60 mL), the mixture was diluted with ethyl acetate (70 mL), and then filtered through diatomaceous earth. The filtrate was extracted with ethyl acetate (70 mL x 3), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent gradient: dichloromethane: methanol = 10: 1) to obtain 4-((1-(5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)-4-nitrophenyl)piperidin-4-yl)methyl)morpholine (2-5) (300 mg, yield: 75.0%).

[0162] LCMS:Rt:0.859min;MS m / z(ESI):416.3[M+H] + .

[0163] Compound 2-6:

[0164]

[0165] The compound 4-((1-(5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)-4-nitrophenyl)piperidin-4-yl)methyl)morpholine (2-5) (300 mg, 0.72 mmol) was dissolved in ethanol (10 mL) at room temperature, and wet palladium / carbon (30 mg, 10% (Pd>=10%, H2O wt%=50%)) was added. The reaction solution was heated to 60°C under a hydrogen atmosphere and stirred for 3 hours until the reaction was complete. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain a crude product 2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(4-(morpholinomethyl)piperidin-1-yl)aniline (2-6) (200 mg, yield: 72.2%).

[0166] LCMS:Rt:0.354min; MS m / z(ESI):386.2[M+H] + .

[0167] Compound 2:

[0168]

[0169] Compound 2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(4-(morpholinomethyl)piperidin-1-yl)aniline (2-6) (200.0 mg, 0.52 mmol) and (6-((5-bromo-2-chloropyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide (1-4) (193 mg, 0.47 mmol) were dissolved in isopropanol (5 mL) at room temperature, and trifluoroacetic acid (592 mg, 5.2 mmol) was added; the reaction solution was heated to 100° C. and stirred for 24 hours. After the reaction was completed, the reaction solution was cooled to room temperature and then concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography (eluent gradient reference Example 1) to obtain the target compound (6-((5-bromo-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(4-(morpholinomethyl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)quinoxaline-5-yl)dimethylphosphine oxide trifluoroacetate (Compound 2) (85.9 mg, yield: 21.4%).

[0170] 1H NMR (400MHz, MeOD): δ8.87(s,1H),8.84(s,1H),8.83-8.76(m,1H),8.27(s,1H),7.87( s,1H),7.63(s,2H),7.60(s,1H),6.87(s,1H),4.08(d,J=12.4Hz,2H),3.89(s,3H),3. 86-3.79(m,2H),3.76(s,3H),3.56(d,J=12.0Hz,2H),3.23-3.16(m,6H),2.74–2.69(m ,2H),2.17(s,3H),2.13(s,3H),2.04(br,1H),1.88(d,J=12Hz,2H),1.54-1.50(m,2H).

[0171] 19 F NMR (376.5MHz, MeOD) δ: -77.21

[0172] 31 P NMR (162.0MHz, MeOD) δ: 53.18.

[0173] LCMS: Rt:4.067min; MS m / z(ESI):761.1,763.1[M+H] + .

[0174] Example 3. Preparation of (6-((5-bromo-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(4-((4-methylpiperazin-1-yl)methyl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide trifluoroacetate (Compound 3)

[0175]

[0176] Referring to the synthesis method of Example 2, morpholine was replaced with N-methylpiperazine to obtain the target compound (6-((5-bromo-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-(4-((4-methylpiperazin-1-yl)methyl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)quinoxaline-5-yl)dimethylphosphine oxide trifluoroacetate (Compound 3).

[0177] 1H NMR (400MHz, MeOD): δ8.87(d,J=7.6Hz,2H),8.75(br,1H),8.26(s,1H),7.90(s,1H),7.65(s,2H),7.57(s,1H), 6.90(s,1H),3.90(s,3H),3.79(s,3H),3.51(br,4H),3.30(br,4H),3.25-3.22(m,2H),2.94-2.91(m,5H),2.79 2.76(m,2H),2.17(s,3H),2.13(s,3H),1.91-1.88(m,3H),1.49-1.46(m,2H).

[0178] 19F NMR (376.5MHz, MeOD) δ: -77.21

[0179] 31 P NMR (162.0MHz, MeOD) δ: 53.23

[0180] LCMS: Rt:3.857min; MS m / z(ESI):774.2,776.2[M+H] +

[0181] Example 4. Preparation of (1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)(morpholino)methanone trifluoroacetate (Compound 4)

[0182]

[0183] Compound 4-2:

[0184]

[0185] Compound 1-(tert-butyloxycarbonyl)piperidine-4-carboxylic acid (1.15 g, 5.0 mmol) was dissolved in 50 mL of N,N-dimethylformamide, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (2.85 g, 7.5 mmol) was added, and stirred at room temperature for 20 minutes. N,N-diisopropylethylamine (1.29 g, 10.0 mmol) and morpholine (653 mg, 7.5 mmol) were added dropwise to the mixture, and the mixture was stirred at room temperature for 0.5 hours. The reaction solution was poured into 100 mL of water and 50 mL of ethyl acetate, the aqueous phase was extracted with ethyl acetate (50 mL x 3), the combined organic phases were washed with saturated brine (100 mL x 2), dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain the target intermediate 4-(morpholine-4-carbonyl)piperidine-1-carboxylic acid tert-butyl ester (4-2) (1.5 g, yield: 100%).

[0186] LCMS: Rt: 1.11min; MS m / z (ESI): 243.1 [M-55].

[0187] Compound 4-3:

[0188]

[0189] Add 20 mL of hydrogen chloride / 1,4-dioxane solution (4M) to the compound 4-(morpholine-4-carbonyl)piperidine-1-carboxylic acid tert-butyl ester (4-2) (1.5 g, 5.0 mmol) and stir at room temperature for 2 hours. LCMS detected that the reaction was complete, and the reaction solution was concentrated and evaporated to dryness to obtain the intermediate morpholine (piperidin-4-yl) ketone hydrochloride (4-3) (1 g, yield: 85.2%).

[0190] LCMS:Rt:1.45min;MS m / z(ESI):199.1[M+H] + .

[0191] Compound 4-4:

[0192]

[0193] The compound morpholine (piperidin-4-yl) ketone hydrochloride (4-3) (600 mg, 2.6 mmol) and the compound 1-bromo-2-fluoro-4-methoxy-5-nitrobenzene (500 mg, 2.0 mmol) were dissolved in 40 mL of acetonitrile, potassium carbonate powder (830 mg, 6.0 mmol) was added to the solution, and the temperature was raised to 90°C for 2 hours. LCMS detected that the reaction was complete, and the reaction solution was cooled to room temperature and filtered through diatomaceous earth. The filtrate was concentrated to dryness under reduced pressure to obtain the target intermediate (1-(2-bromo-5-methoxy-4-nitrophenyl) piperidin-4-yl) (morpholino) ketone (4-4) (1.0 g crude product, yield: 100%).

[0194] LCMS:Rt:1.033min;MS m / z(ESI):428.0[M+H] + .

[0195] Compound 4-5:

[0196]

[0197] Compound (1-(2-bromo-5-methoxy-4-nitrophenyl)piperidin-4-yl)(morpholino)methanone (4-4) (1 g, 2.0 mmol) and compound 1-methylpyrazole-4-boronic acid pinacol ester (625 mg, 3.0 mmol) were dissolved in 1,4-dioxane (50 mL), 5 mL of saturated sodium carbonate (424 mg, 4.0 mmol) aqueous solution was added dropwise, the solution was ventilated with argon for 3 times, [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (146 mg, 0.2 mmol) was added, argon was replaced 4 times, and the temperature was raised to 90°C for reaction for 18 hours. LCMS detected that the reaction was basically complete. The reaction solution was cooled to room temperature, added to water (100 mL), extracted with ethyl acetate (50 mL × 3), and the combined organic phases were washed with saturated brine (100 mL × 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give the target intermediate (1-(5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)-4-nitrophenyl)piperidin-4-yl)(morpholino)methanone (4-5) (900 mg crude product, yield: 100%).

[0198] LCMS:Rt:1.35min; MS m / z(ESI):430.1[M+H] + .

[0199] Compounds 4-6:

[0200]

[0201] Compound (1-(5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)-4-nitrophenyl)piperidin-4-yl)(morpholino)methanone (4-5) (900 mg, 2.0 mmol) was dissolved in methanol (40 mL), wet palladium / carbon (150 mg) was added, the reaction system was evacuated and filled with hydrogen, and heated to 50°C under a hydrogen atmosphere and stirred for 2 hours. LCMS detected that the reaction was complete. The reaction solution was cooled to room temperature, and the catalyst was removed by filtration through diatomaceous earth. The filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by C18 reverse phase column [H2O (0.03% NH3·H2O)-MeCN / H2O (0.03% NH3·H2O) = 40%] to obtain the target intermediate (1-(4-amino-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)(morpholino)methanone (4-6) (200 mg, yield: 25%).

[0202] LCMS:Rt:1.77min; MS m / z(ESI):400.1[M+H] + .

[0203] Compound 4:

[0204]

[0205] At room temperature, (6-((5-bromo-2-chloropyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide (1-4) (155 mg, 0.375 mmol) and (1-(4-amino-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)(morpholino)methanone (4-6) (150 mg, 0.375 mmol) were dissolved in isopropanol (8 mL) and stirred at room temperature, and trifluoroacetic acid (0.3 mL, 3.755 mmol) was added. After the addition was completed, the reaction was placed in an oil bath at 100°C and heated under reflux for 14 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The crude product was purified by preparative HPLC (eluent gradient reference Example 1) to give (1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxaline-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)(morpholino)methanone trifluoroacetate (Compound 4) (150 mg, yield: 51.5%).

[0206] 1H NMR(400MHz,MeOD)δ:8.88(d,J=2.3Hz,2H),8.74(s,1H),8.28(s,1H),8.02(s,1H),7.64(br,2H),7.52(s,1H),6.91(s,1H),3.91(s,3H),3 .84(s,3H),3.69-3.66(m,8H),3.25(d,J=10.8Hz,2H),2.85-2.81(m,3H),2.18(s,3H),2.14(s,3H),1.97-1.90(m,2H),1.87-1.78(m,2H).

[0207] 19 F NMR (376.5MHz, MeOD) δ: -77.49

[0208] 31 P NMR (162.0MHz, MeOD) δ: 53.25.

[0209] LCMS: Rt:6.301min; MS m / z(ESI):775.2,777.2[M+H] + .

[0210] Example 5. Preparation of (1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)(4-methylpiperazin-1-yl)methanone trifluoroacetate (Compound 5)

[0211]

[0212] Referring to the synthesis method of Example 4, morpholine was replaced with N-methylpiperazine to obtain (1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxaline-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)(4-methylpiperazin-1-yl)methanone trifluoroacetate (Compound 5).

[0213] 1H NMR(400MHz,MeOD)δ:8.88(d,J=1.8Hz,1H),8.85(d,J=1.8Hz,1H),8.75(br,1H) ,8.28(s,1H),7.98(s,1H),7.66(br,2H),7.54(s,1H),6.89(s,1H),3.91(s,3H), 3.81(s,3H),3.52(br,4H),3.26-3.13(m,6H),2.95(s,3H),2.88-2.83(m,1H),2. 80-2.75(m,2H),2.17(s,3H),2.14(s,3H),1.92-1.90(m,2H),1.83-1.79(m,2H).

[0214] 19 F NMR (376.5MHz, MeOD) δ: -77.31

[0215] 31 P NMR (162.0MHz, MeOD) δ: 53.23.

[0216] LCMS: Rt:3.949min; MS m / z(ESI):788.2,790.2[M+H] + .

[0217] Example 6. Preparation of (6-((2-((4-((1,4-oxazepan-4-yl)methyl)-2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-5-bromopyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide trifluoroacetate (Compound 6)

[0218]

[0219] Compound 6-2:

[0220]

[0221] 4-Bromo-3-methylphenol (5.61 g, 30 mmol) and ytterbium trifluoromethanesulfonate (1.86 g, 3.0 mmol) were added to dichloromethane (150 mL) at room temperature, and then fuming nitric acid (1.9 mL) was slowly added dropwise. The mixture was stirred at room temperature for 1 h. 150 mL of water was added, and the mixture was extracted with dichloromethane three times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column (eluent gradient: petroleum ether) to obtain 4-bromo-5-methyl-2-nitrophenol (6-2) (3.0 g, yield: 43%). 1H NMR(400MHz, CDCl3)δ:10.42(s,1H),8.27(s,1H),7.05(s,1H),2.44(s,3H).

[0222] Compound 6-3:

[0223]

[0224] 4-Bromo-5-methyl-2-nitrophenol (6-2) (3.0 g, 12.93 mmol), potassium carbonate (7.14 g, 51.72 mmol) and iodomethane (7.34 g, 51.72 mmol) were added to acetonitrile (100 mL) at room temperature, and the temperature was raised to 60 degrees and stirred for 16 hours. The reaction solution was filtered, the filtrate was concentrated under reduced pressure, 100 mL of ethyl acetate was added to dissolve, and the solution was washed with 60 mL of water and 60 mL of saturated brine, respectively, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the intermediate 1-bromo-4-methoxy-2-methyl-5-nitrobenzene (6-3) (2.6 g, yield: 82%).

[0225] 1 H NMR (400MHz, CDCl3) δ: 8.07 (s, 1H), 6.96 (s, 1H), 3.96 (s, 13H), 2.46 (s, 3H).

[0226] Compound 6-4:

[0227]

[0228] 1-Bromo-4-methoxy-2-methyl-5-nitrobenzene (6-3) (1.6 g, 6.5 mmol), N-bromosuccinimide (1.27 g, 7.15 mmol), azobisisobutyronitrile (214 mg, 1.30 mmol) were added to 1,2-dichloroethane (20 mL) at room temperature, and the mixture was heated to 85 degrees and stirred for 3 hours under argon protection. The reaction solution was concentrated under reduced pressure and dried, and the residue was dissolved in 100 mL of ethyl acetate, washed with 60 mL of water and 60 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the intermediate 1-bromo-2-(bromomethyl)-4-methoxy-5-nitrobenzene (6-4) (1.2 g, yield: 57%), which was directly used in the next step. Compound 6-5:

[0229]

[0230] 1-Bromo-2-(bromomethyl)-4-methoxy-5-nitrobenzene (6-4) (600 mg, 1.85 mmol), homomorpholine hydrochloride (281 mg, 2.04 mmol) and potassium carbonate (511 mg, 3.7 mmol) were added to acetonitrile (10 mL) at room temperature, and the mixture was stirred at 60°C for 2 hours. The reaction solution was directly concentrated under reduced pressure, and the residue was purified by silica gel column (eluent gradient: dichloromethane / methanol = 10 / 1) to obtain the intermediate 4-(2-bromo-5-methoxy-4-nitrobenzyl)-1,4-oxazepane (6-5) (400 mg, yield: 63%). LCMS: Rt: 0.409 min; MS m / z (ESI): 345.0 [M+H] + .

[0231] Compound 6-6:

[0232]

[0233] 4-(2-Bromo-5-methoxy-4-nitrobenzyl)-1,4-oxazepine (6-5) (400 mg, 1.16 mmol), 1-methylpyrazole-4-boronic acid pinacol ester (362 mg, 1.74 mmol) and potassium phosphate (739 mg, 3.48 mmol) were added to dioxane (15 mL) and water (1.5 mL) at room temperature, and the atmosphere was replaced with argon four times. [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (82 mg, 0.116 mmol) was added, and the atmosphere was replaced with argon four times. The temperature was raised to 100°C and stirred for reaction for 4 hours. The reaction solution was directly concentrated under reduced pressure, and the residue was purified by silica gel column (eluent gradient: dichloromethane / methanol = 20 / 1) to obtain the intermediate 4-(5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)-4-nitrobenzyl)-1,4-oxazepane (6-6) (250 mg, yield: 72%).

[0234] LCMS:Rt:0.393min;MS m / z(ESI):347.0[M+H] + .

[0235] Compound 6-7:

[0236]

[0237] 4-(5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)-4-nitrobenzyl)-1,4-oxazepane (6-6) (250 mg, 0.722 mmol) was dissolved in ethanol (20 mL) at room temperature, wet palladium / carbon (100 mg, 10% (Pd>=10%, H2Owt%=50%)) was added, and the mixture was heated to 50°C and stirred for 1 hour under a hydrogen atmosphere. The catalyst was removed by filtration with diatomaceous earth, and the filtrate was concentrated under reduced pressure to obtain 4-((1,4-oxazepane-4-yl)methyl)-2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)aniline (6-7) (200 mg, yield: 63%).

[0238] LCMS:Rt:0.385min; MS m / z(ESI):317.1[M+H] + .

[0239] Compound 6:

[0240]

[0241] 4-((1,4-oxazepan-4-yl)methyl)-2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)aniline (6-7) (80 mg, 0.253 mmol), (6-((5-bromo-2-chloropyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide (1-4) (83 mg, 0.202 mmol), and concentrated hydrochloric acid (6 drops) were added to isopropanol (15 mL) at room temperature. The reaction solution was heated to 85°C under an argon atmosphere and stirred for 13 hours. The reaction mixture was concentrated under reduced pressure, and the residue was added to methanol (5 mL). The filtrate was filtered and purified by preparative HPLC (eluent gradient reference Example 1) to give the target compound (6-((2-((4-((1,4-oxazepan-4-yl)methyl)-2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-5-bromopyrimidin-4-yl)amino)quinoxaline-5-yl)dimethylphosphine oxide trifluoroacetate (Compound 6) (16 mg, yield: 9.1%).

[0242] 1H NMR (400MHz, MeOD): δ8.86(s,2H),8.78-8.74(m,1H),8.36(s,1H),8.26(s,1H),7.64–7.53(m,2H),7.32(s,1H),7.20(s,1H),4.47(s, 2H),4.02(s,3H),3.80(s,3H),3.78-3.65(m,4H),3.41-3.37(m,2H),3.23–2.98(m,2H),2.17(s,3H),2.13(s,3H),2.05-1.904(m,2H)

[0243] 31 P NMR (162.0MHz, MeOD): δ52.93.

[0244] 19 F NMR (376.5MHz, MeOD): δ-76.91.

[0245] LCMS:Rt:.0995min;MS m / z(ESI):692.1,694.1[M+H] + .

[0246] Example 7, Preparation of (6-((2-((4-((3-oxo-8-azabicyclo[3.2.1]octan-8-yl)methyl)-2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-5-bromopyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide (Compound 7)

[0247]

[0248] Referring to the synthesis method of Example 6, the homomorpholine hydrochloride was replaced with 3-oxa-8-azabicyclo[3.2.1]octane hydrochloride to obtain (6-((2-((4-((3-oxo-8-azabicyclo[3.2.1]octane-8-yl)methyl)-2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-5-bromopyrimidin-4-yl)amino)quinoxaline-5-yl)dimethylphosphine oxide trifluoroacetate (Compound 7).

[0249] 1H NMR (400MHz, DMSO-d6): δ12.71(s,1H),8.89–8.79(m,3H),8.44(s,1H),8.31(s,1H),7.93(s,1H),7.67(s,1H),7.57(br,2H),7.21(s,1H),3. 85(s,3H),3.78(s,3H),3.59-3.57(m,2H),3.46–3.40(m,4H),3.06(br ,2H),2.04(s,3H),2.00(s,3H),1.99-1.95(s,2H),1.78-1.76(m,2H).

[0250] 31 P NMR (162.0MHz, DMSO-d6): δ49.32.

[0251] LCMS:Rt:1.004min;MS m / z(ESI):704.1,706.1[M+H] + .

[0252] Example 8. Preparation of (6-((2-((4-(4-((1,4-oxazepan-4-yl)methyl)piperidin-1-yl)-2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-5-bromopyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide trifluoroacetate (Compound 8)

[0253]

[0254] Referring to the synthesis method of Example 2, morpholine was replaced with homomorpholine to obtain (6-((2-((4-(4-((1,4-oxazepan-4-yl)methyl)piperidin-1-yl)-2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-5-bromopyrimidin-4-yl)amino)quinoxaline-5-yl)dimethylphosphine oxide trifluoroacetate (Compound 8).

[0255] 1H NMR(400MHz,MeOD)δ:8.86(s,1H),8.81(br,2H),8.27(s,1H),7.83(s,1H),7.76(s ,1H),7.59(br,2H),6.87(s,1H),3.96-3.78(m,7H),3.73(s,3H),3.68-3.61(m,2H) ,3.49-3.34(m,2H),3.27-3.15(m,4H),2.72(t,J=11.4Hz,2H),2.28-2.18(m,2H), 2.17(s,3H),2.14(s,3H),2.07-1.92(m,1H),1.91-1.79(m,2H),1.53-1.52(m,2H).

[0256] 19 F NMR (376.5MHz, MeOD) δ: -77.18

[0257] 31 P NMR (162.0MHz, MeOD) δ: 53.09.

[0258] LCMS:Rt:4.115min;MS m / z(ESI):775.2,777.2[M+H] + .

[0259] Example 9. Preparation of (1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)((2S,6R)-2,6-dimethylmorpholinyl)methanone trifluoroacetate (Compound 9)

[0260]

[0261] Referring to the synthesis method of Example 4, morpholine was replaced with cis-2,6-dimethylmorpholine to obtain (1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxaline-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)(2S,6R)-2,6-dimethylmorpholinyl)methanone trifluoroacetate (Compound 9).

[0262] 1H NMR(400MHz,MeOD)δ8.90-8.83(m,2H),8.76(br,1H),8.27(s,1H),8.01(s,1H),7.6 5(br,2H),7.48(br,1H),6.91(s,1H),4.42(d,J=13.1Hz,1H),3.94-3.91(m,4H),3.8 2(s,3H),3.64-3.47(m,2H),3.25-3.22(m,2H),2.92-2.66(m,4H),2.43-2.30(m,1H) ,2.17(s,3H),2.13(s,3H),1.94-1.91(m,2H),1.79-1.76(m,2H).1.22-1.18(m,6H).

[0263] 19 F NMR (377 MHz, MeOD) δ-77.38.

[0264] 31 P NMR (162 MHz, MeOD) δ 53.194.

[0265] LCMS:Rt:7.397min;MS m / z(ESI):803.2,805.2[M+H] + .

[0266] Example 10. Preparation of (3-oxo-8-azabicyclo[3.2.1]octan-8-yl)(1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)methanone trifluoroacetate (Compound 10)

[0267]

[0268] Referring to the synthesis method of Example 4, morpholine was replaced with 3-oxa-8-azabicyclo[3.2.1]octane hydrochloride to obtain (3-oxo-8-azabicyclo[3.2.1]octane-8-yl)(1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxaline-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)methanone trifluoroacetate (Compound 10).

[0269] 1H NMR (400MHz, MeOD) δ8.87-8.74(m,3H),8.27(s,1H),8.03(s,1H),7.65(br,2H),7.48(br,1H),6.90(s,1H),4.56-4.54(m,1H),4.37(d,J=5.3Hz,1H) ,3.91(s,3H),3.83(s,3H),3.73–3.62(m,4H),3.28-3.24(m,2H),2.77-2. 69(m,3H),2.16(s,3H),2.13(s,3H)2.10–1.97(m,4H),1.95–1.71(m,4H).

[0270] 19 F NMR (377 MHz, MeOD) δ-77.37.

[0271] 31 P NMR (162 MHz, MeOD) δ 53.22.

[0272] LCMS:Rt:6.597min;MS m / z(ESI):801.2,803.2[M+H] + .

[0273] Example 11. Preparation of (6-((5-bromo-2-((4-(4-(((2S,6R)-2,6-dimethylmorpholino)methyl)piperidin-1-yl)-2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)pyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide trifluoroacetate (Compound 11)

[0274]

[0275] Referring to the synthesis method of Example 2, morpholine was replaced with cis-2,6-dimethylmorpholine to obtain (6-((5-bromo-2-((4-(4-(((2S,6R)-2,6-dimethylmorpholine)methyl)piperidin-1-yl)-2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)pyrimidin-4-yl)amino)quinoxaline-5-yl)dimethylphosphine oxide trifluoroacetate (Compound 11).

[0276] 1H NMR (400MHz, MeOD): δ8.84-8.21(m,3H),8.28(s,1H),7.86(s,1H),7.69(br,2H) ,7.60(br,1H),6.87(s,1H),3.92-3.90(m,5H),3.76(s,3H),3.55-3.51(m,2H),3 .24-3.21(m,2H),3.17-3.15(m,2H),2.75-2.69(m,4H),2.17(s,3H),2.14(s,3H ),2.06(br,1H),1.89-1.86(m,2H),1.55-1.47(m,2H),1.27(s,3H),1.25(s,3H).

[0277] 19 F NMR (377 MHz, MeOD): δ-77.24.

[0278] 31 P NMR (162 MHz, MeOD): δ 53.18.

[0279] LCMS:Rt:1.088min; MS m / z(ESI):789.0,791.0[M+H] + .

[0280] Example 12, Preparation of (6-((5-bromo-2-((4-(4-((3,3-difluoropyrrolidin-1-yl)methyl)piperidin-1-yl)-2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)pyrimidin-4-yl)amino)quinoxalin-5-yl)dimethylphosphine oxide trifluoroacetate (Compound 12)

[0281]

[0282] Referring to the synthesis method of Example 2, morpholine was replaced with 3,3-difluoropyrrolidine to obtain (6-((5-bromo-2-((4-(4-((3,3-difluoropyrrolidin-1-yl)methyl)piperidin-1-yl)-2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)pyrimidin-4-yl)amino)quinoxaline-5-yl)dimethylphosphine oxide trifluoroacetate (Compound 12).

[0283] 1H NMR (400MHz, MeOD): δ8.86-8.77(m,3H),8.27(s,1H),7.86(s,1H),7.71(s,1H),7.67-7.58(m,2H),6.86(s,1H),4.02-3.96(m,2H),3.90(s,3H) ),3.82-3.75(m,5H),3.33(br,2H),3.21(d,J=11.4Hz,2H),2.74-2.64( m,4H),2.17(s,3H),2.13(s,3H),1.94-1.86(m,3H),1.54-1.46(m,2H).

[0284] 19 F NMR (377MHz, MeOD): δ-77.09,-96.03.

[0285] 31 P NMR (162 MHz, MeOD): δ 53.15.

[0286] LCMS:Rt:1.136min; MS m / z(ESI):781.1,783.1[M+H] + .

[0287] Example 13. Preparation of 3-((1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)methyl)-1,3-oxazepine-2-one trifluoroacetate (Compound 13)

[0288]

[0289] Compound 13-2:

[0290]

[0291] Benzyl 4-formylpiperidine-1-carboxylate (2.0 g, 8.09 mmol), compound 3-amino-1-propanol (668 mg, 8.90 mmol) and acetic acid (728 mg, 12.13 mmol) were dissolved in 1,2-dichloroethane (20 mL) at room temperature, and the reaction was stirred at room temperature for 2 hours. Sodium triacetoxyborohydride (3.4 g, 16.18 mmol) was added and reacted at room temperature for 2 hours. 100 mL of water was added to quench the reaction, and the mixture was extracted with dichloromethane (50 mL x 3). The organic phase was washed with saturated brine (50 mL), dried over sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain the target compound 4-(((3-hydroxypropyl)amino)methyl)piperidine-1-carboxylic acid benzyl ester (13-2) (2.4 g, yield: 97%), which was directly used in the next step.

[0292] LCMS:Rt:0.763min;MS m / z(ESI):307.6[M+H] + .

[0293] Compound 13-3:

[0294]

[0295] At room temperature, benzyl 4-(((3-hydroxypropyl)amino)methyl)piperidine-1-carboxylate (13-2) (2.4 g, 7.84 mmol) and triethylamine (4.0 g, 39.2 mmol) were dissolved in tetrahydrofuran (35 mL), and N,N-carbonyldiimidazole (1.5 g, 9.41 mmol) was slowly added. The mixture was reacted at room temperature for 16 hours. After the reaction was complete, ethyl acetate (100 mL) and water (100 mL) were added for separation. The organic phase was washed with saturated brine, dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column (petroleum ether: ethyl acetate = 2:1) to obtain the target compound benzyl 4-((2-oxo-1,3-oxazahexyl)methyl)piperidine-1-carboxylate (13-3) (1.5 g, yield: 57%).

[0296] LCMS:Rt:1.490min; MS m / z(ESI):333.2[M+H] + .

[0297] Compound 13-4:

[0298]

[0299] At room temperature, benzyl 4-((2-oxo-1,3-oxazahexyl-3-yl)methyl)piperidine-1-carboxylate (13-3) (1.5 g, 4.52 mmol) was dissolved in 15 mL of ethanol, and wet palladium / carbon (150 mg (Pd>=10%, H2O wt%=50%)) was added, replaced with hydrogen three times, and reacted at room temperature for 4 hours under a hydrogen atmosphere. After the reaction was complete, the catalyst was removed by filtration with diatomaceous earth, and the filtrate was concentrated to dryness under reduced pressure to obtain 3-(piperidin-4-ylmethyl)-1,3-oxazahexyl-2-one (13-4) (700 mg, yield: 78%).

[0300] LCMS:Rt:0.303min; MS m / z(ESI):199.2[M+H] + .

[0301] The remaining steps refer to the synthesis method of Example 2, replacing 4-(piperidin-4-ylmethyl)morpholine (2-3) with 3-(piperidin-4-ylmethyl)-1,3-oxazepine-2-one (13-4) to obtain 3-((1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxaline-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)methyl)-1,3-oxazepine-2-one trifluoroacetate (Compound 13).

[0302] 1 H NMR(400MHz,MeOD)δ:8.87-8.86(m,3H),8.27(s,1H),7.93(s,1H),7.70(br,2 H),7.54(br,1H),6.93(s,1H),4.31-4.28(m,2H),3.91(s,3H),3.81(s,3H),3. 44-3.41(m,2H),3.33(br,2H),3.25(br,2H),2.77(br,2H),2.17(s,3H),2.14( s,3H),2.09-2.04(m,2H),1.94(br,1H),1.17-1.14(m,2H),1.52-1.44(m,2H).

[0303] 19 F NMR (376.5MHz, MeOD): δ-77.39

[0304] 31 P NMR (162 MHz, MeOD): δ 53.19

[0305] LCMS:Rt:6.290min; MS m / z(ESI):775.2,777.2[M+H] + .

[0306] Example 14. Preparation of 1-(4-((1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)ethan-1-one trifluoroacetate (Compound 14)

[0307]

[0308] Referring to the synthesis method of Example 2, 1-(4-((1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-(1-methyl-1H-pyrazol-4-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)ethan-1-one trifluoroacetate (Compound 14) was obtained.

[0309] 1 H NMR(400MHz,MeOD)δ:8.86(d,J=1.8Hz,1H),8.82-8.81(m,2H),8.27(s,1H),7.84 (s,1H),7.75(s,1H),7.70-7.53(m,2H),6.87(s,1H),3.91(s,3H),3.73(s,3H),3 .70-3.32(m,6H),3.26-2.92(m,6H),2.72(t,J=11.3Hz,2H),2.17(s,3H),2.16(s ,3H),2.14(s,3H),2.10-1.95(m,1H),1.88(d,J=12.2Hz,2H),1.59-1.46(m,2H).

[0310] 19 F NMR (376.5MHz, MeOD) δ: -77.19

[0311] 31 P NMR (162.0MHz, MeOD) δ: 53.10

[0312] LCMS:Rt:3.923min;MS m / z(ESI):802.3,804.3[M+H] + .

[0313] Referring to the synthesis method of the above embodiment, the present invention also synthesized the following compounds, and their characterization data are:

[0314]

[0315]

[0316]

[0317] Biological activity and related properties test examples

[0318] The compounds in the following test examples are all prepared according to the methods of the above embodiments of the present application. The test example compounds can be in the form of free base or its trifluoroacetate salt, which is determined according to the specific form of the product prepared in the above embodiments.

[0319] Test Example 1: BaF3 cell anti-proliferation experiment

[0320] Experimental Materials:

[0321] RPMI1640 was purchased from Gibco (USA).

[0322] FBS was purchased from Excell (China).

[0323] IL-3 Recombinant Mouse Protein was purchased from Gibco (USA).

[0324] Cell Luminescent Cell Viability kit was purchased from Promega (USA).

[0325] BaF3 cells were purchased from Riken (Japan).

[0326] BaF3 / EGFR-WT and BaF3 / EGFR-Del19 / T790M / C797S cells were constructed by Crown Biotech (Taicang) Co., Ltd.

[0327] BaF3 culture medium: RPMI1640+10% FBS+8ng / ml IL-3.

[0328] BaF3 / EGFR-WT, BaF3 / EGFR-Del19 / T790M / C797S culture medium: RPMI1640+10% FBS.

[0329] Plate reader: EnVision (PerkinElmer, USA).

[0330] Experimental methods:

[0331] Adjust the cell concentration, plant 2000 BaF3, BaF3 / EGFR-WT or BaF3 / EGFR-Del19 / T790M / C797S cells in each well of a 96-well plate, prepare 1000X test compound stock solution with DMSO, and dilute the test compound 3-fold with DMSO (9 concentrations in total), then dilute 100-fold with the corresponding cell culture medium, add 10μl (10X concentration) of the test compound to each well (three replicates for each compound and each concentration), and culture for 72 hours at 37°C with 5% CO2. After 72 hours, add 50μl Cell Titer-Glo to each well, mix on a shaker for 2 minutes, incubate for 10 minutes, and read with EnVision.

[0332] Data Analysis:

[0333] Cell activity was plotted using GraphPad Prism version 5, and the curves were fitted using a nonlinear regression model with a sigmoidal dose response, from which the IC 50 The test results are shown in Table 1.

[0334] Table 1. Results of BaF3 cell proliferation experiment

[0335]

[0336]

[0337] "NA" indicates that the antiproliferative activity of the test compound was not tested.

[0338] Test Example 2: PC9 EGFR-Del19 / T790M / C797S and HEK293T cell proliferation assay

[0339] Experimental Materials:

[0340] RPMI1640 was purchased from Gibco (USA).

[0341] DMEM was purchased from Gibco (USA).

[0342] FBS was purchased from Gibco (USA).

[0343] Puromycin was purchased from Invitrogen (USA).

[0344] Trypsin was purchased from Invitrogen (USA).

[0345] DMSO was purchased from Sigma (USA).

[0346] Cell Counting Kit-8 (CCK-8) cell proliferation toxicity detection kit was purchased from Dongren Chemical Technology (Shanghai) Co., Ltd.

[0347] PC9 EGFR-Del19 / T790M / C797S cells were constructed by Crown Biotech (Taicang) Co., Ltd.

[0348] HEK293T cells were purchased from ATCC (USA).

[0349] PC9 EGFR-Del19 / T790M / C797S culture medium: RPMI1640+10% FBS+0.5ug / mL puromycin.

[0350] HEK293T culture medium: DMEM + 10% FBS.

[0351] Plate reader: EnVision (PerkinElmer, USA).

[0352] Experimental methods:

[0353] Cells were cultured for 2-3 days until the confluence reached 80-90%. Cells were digested with trypsin, resuspended by centrifugation, and counted. The cell concentration was adjusted to 1000 cells per well (HEK293T) and 3000 cells per well (PC9 EGFR-Del19 / T790M / C797S). The volume was 90 μl, and the test compound was diluted 3-fold with DMSO (8 concentrations in total). After 20-fold dilution with serum-free medium, 10 μl (10X concentration) of the test compound was added to each well (two replicates for each compound and each concentration), and cultured at 37°C for 72 hours with 5% CO2. After 72 hours, 10 μl CCK-8 was added to each well, centrifuged and mixed, and cultured at 37°C for 1-4 hours. Mixed on a shaker for 2 minutes, incubated for 10 minutes, and OD450 was read using EnVision.

[0354] Data Analysis:

[0355] The inhibition rate was calculated according to the following formula:

[0356] Inhibition % = (OD cell control –OD sample ) / (OD cell control –OD media control )*100

[0357] IC50 data were calculated using 4-parameter fitting using IDBS Xlfit Model 205

[0358] The test results are shown in Table 2.

[0359] Table 2, PC9 and HEK293T cell proliferation assay results

[0360]

[0361] Test Example 3: In vivo efficacy study in mice

[0362] Experimental reagents:

[0363] PC9-EGFR-Del19 / T790M / C797S: CrownBio modified monoclonal cells;

[0364] RPMI-1640 culture medium: Gibco, REF: 61870-036;

[0365] Fetal bovine serum: Gibco, REF: 10099-141C;

[0366] Penicillin-streptomycin: Gibco, Cat No.: 15240-122;

[0367] 0.25% pancreatin-EDTA: Gibco, Cat No.: 25200-072;

[0368] D-PBS (calcium-free and magnesium-free phosphate buffer): Hyclone, Cat. No.: SH30256.01;

[0369] Matrigel: Corning, Cat No.: 356237.

[0370] Experimental methods:

[0371] Animal information: BALB / c nude mice, female, 6-8 weeks old, weighing approximately 18-22 grams, were purchased from Shanghai Lingchang Biotechnology Co., Ltd. The mice were housed in an SPF-grade environment with separate ventilation in each cage. All animals had free access to standard certified commercial laboratory diets and free drinking water.

[0372] Cell culture: PC9 stable cell line of lung cancer (PC9-EGFR-Del19 / T790M / C797S) overexpressing EGFR-Del19 / T790M / C797S mutant was cultured in monolayer in vitro. The culture conditions were RPMI-1640 (cell culture medium) with 10% fetal bovine serum and 1% penicillin-streptomycin solution added and cultured in an incubator at 37°C and 5% CO2. The cells were routinely digested and passaged twice a week with 0.25% trypsin-EDTA digestion solution. When the cell saturation was 85%-90% and the number reached the requirement, the cells were collected and counted.

[0373] Cell inoculation: 0.1 ml / (containing 5×10 6 )PC9-EGFR-Del19 / T790M / C797S cell suspension (D-PBS:Matrigel=1:1) was subcutaneously inoculated on the right back of each mouse. On the 8th day after inoculation, the average tumor volume was measured to be about 115 mm 3 At 14:00, the random stratified grouping method was used to start the grouping and drug administration according to the tumor volume and animal weight. D-PBS is a phosphate buffered saline without calcium and magnesium ions, and Matrigel is a matrix gel.

[0374] Administration: The dosage of compound 8 was 30 mg / kg or 60 mg / kg, administered orally (PO), once a day (QD) x 3 weeks; the vehicle control group had 5 mice per group, and the drug administration group had 6 mice per group.

[0375] Tumor measurements and experimental parameters:

[0376] Tumor diameter was measured with a vernier caliper twice a week. The tumor volume was calculated as: V = 0.5 axb 2 , a and b represent the long diameter and short diameter of the tumor, respectively. The body weight of mice was measured twice a week.

[0377] The anti-tumor efficacy of the compound was evaluated by tumor growth inhibition rate TGI (%). TGI (%) = [(1-(average tumor volume at the end of drug administration in a treatment group - average tumor volume at the beginning of drug administration in the treatment group) / (average tumor volume at the end of treatment in the solvent control group - average tumor volume at the beginning of treatment in the solvent control group)] x 100%.

[0378] Experimental results:

[0379] See Table 3 and Figure 1 There was no death in any group of mice.

[0380] Table 3. Tumor volume of PC9-EGFR-Del19 / T790M / C797S subcutaneous tumor model

[0381]

[0382]

[0383] Experimental conclusion:

[0384] In the mouse subcutaneous transplant tumor PC9-EGFR-Del19 / T790M / C797S model, compound 8 of the present invention had a significant inhibitory effect on tumor growth when orally administered at 30 mg / kg or 60 mg / kg once a day, and showed a good dose-response relationship.

Claims

1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: in, R 1 is selected from pyrazolyl, the pyrazolyl being optionally substituted by R 1a Substitute, the R 1a Selected from C 1 -C 3 alkyl; R 2 Selected from Br; X is selected from CH; Q 1 is selected from a 5-6 membered heterocyclylene group, wherein the 5-6 membered heterocyclylene group is optionally substituted by R 3a replace; Q 2 is selected from 4-8 membered heterocyclic groups, wherein the 4-8 membered heterocyclic groups are optionally substituted by R 4a replace; L is selected from C 1 -C 3 Alkylene, C 1 -C 3 Alkylene-O, C(=O), NH, N(C 1 -C 3 alkyl), O or S; R 3a , R 4a are independently selected from halogen, CN, oxo, OH, C 1 -C 6 Alkoxy, C 1 -C 3 Acyl or optionally R b Substituted with the following groups: NH 2 , C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl or 3-6 membered heterocyclic group; R b Independently selected from halogen, CN, OH, NH 2 , C 1 -C 3 Alkyl or C 1 -C 3 Alkoxy; The compound represented by formula (I) does not contain 2. The compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, It is characterized in that The Q 1 Selected from Said Optional R 3a replace.

3. A compound of formula (I) according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, It is characterized in that R 3a Selected from halogen, cyano or C 1 -C 3 alkyl.

4. The compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, It is characterized in that The Q 2 Selected from Said Optional R 4a replace.

5. The compound of formula (I) according to claim 1 or 4 or a pharmaceutically acceptable salt thereof, It is characterized in that R 4a Selected from halogen, oxo, C 1 -C 3 Acyl, C 1 -C 3 Alkyl or optionally C 1 -C 3 Alkyl substituted NH 2 .

6. The compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, It is characterized in that L is selected from CH 2 , CH 2 O、CH 2 CH 2 CH 2 O, C(=O), NCH 3 or O.

7. The compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, It is characterized in that Structural unit Selected from 8. The following compound or a pharmaceutically acceptable salt thereof:

9. A pharmaceutical composition comprising the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

10. Use of the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof, or the composition according to claim 9, in the preparation of a medicament for preventing or treating EGFR-mediated diseases.

Citation Information

Patent Citations

  • 2-aminopyrimidine compounds as well as pharmaceutical compositions and applications thereof

    CN105601573A

  • Substituted diaminopyrimidine compound and application thereof in preparation of antineoplastic drugs

    CN106831730A

  • Novel aminopyrimidine EGFR inhibitor

    CN112538072A

  • Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor

    WO2019015655A1